- On October 10 (local time), the
U.S. trade commission has affirmed that
there was no violation of Section 337
- The ITC investigation has
been terminated.
- Hugel will accelerate its global medical aesthetics
businesses as the issues are cleared up
SEOUL,
South Korea, Oct. 10,
2024 /PRNewswire/ -- Hugel Inc., a leading global
medical aesthetics company, announced that the Administrative Law
Judge (ALJ) for its U.S. International Trade Commission (ITC)
investigation issued the final determination on October 10 (local time) that "there is no
violation of Section 337" based on Medytox's allegation of unfair
practices concerning the importation of certain botulinum
neurotoxin (BTX) products into the United
States (Inv. No. 337-TA-1313).
The ITC reviewed
the initial determination and affirmed that there was no violation
of Section 337 on October 10 (local
time). Then this investigation is terminated.
History of the case: In March
2022, Medytox filed a complaint with the ITC requesting an
investigation against Hugel and Hugel America, Inc. and
Croma-Pharma GmbH. After Medytox verified the evidence submitted by
Hugel through the discovery phase, Medytox withdrew the claim for
misappropriation of trade secrets regarding the botulinum strain in
September and October of 2023 and then withdrew the claims on trade
secrets misappropriation of manufacturing processes for botulinum
toxin in January 2024. In its initial
determination in June 2024, ALJ said
the evidence submitted to the commission did not support Medytox's
claim of strain theft and conversion.
"With the ITC's final determination clearing any
uncertainties surrounding Hugel's business operations in the U.S.,
we will accelerate our business expansion in the U.S. We will
strive to strengthen the corporate credibility and shareholder
value and will seek continuous growth in global markets", a Hugel
official said.
About Hugel
Established in 2001, Hugel is a leading global medical
aesthetics company that manufactures injectables for skin
rejuvenation such as botulinum toxin, hyaluronic acid fillers and
skin boosters as well as tissue-lifting threads and cosmetics
products. The company is the only South Korean supplier to the
world's three largest botulinum toxin markets, the US, China and Europe. It exports medical aesthetic products
and devices to around 70 countries and operates eight global
subsidiaries in the US, Australia,
Canada, Taiwan, China, Hong
Kong and Singapore.
Contact:
Jihyun Kim, Manager of the PR Team, Hugel
jihyun.kim@hugel-inc.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/itc-issues-final-ruling-in-favor-of-hugel-no-violation-of-section-337-302273509.html
SOURCE Hugel